Here are the 10-K annual reports from Profusa, Inc. (PFSA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow PFSA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PFSA filings page.
Profusa, Inc. files its annual report describing a transition from a SPAC structure to a digital health company developing long‑term injectable biosensors. The firm completed a 1‑for‑75 reverse stock split in February 2026 and had 4,410,268 common shares outstanding as of April 14, 2026, with non‑affiliate equity valued at about $1.3 million as of June 30, 2025.
Profusa’s Lumee™ platform uses subcutaneous hydrogel sensors and external optical readers to generate continuous oxygen and glucose data. Lumee Oxygen holds CE approval in Europe and is being advanced toward updated MDR compliance and a planned U.S. launch in 2026, subject to FDA authorization. Lumee Glucose is an investigational continuous glucose monitoring system with multi‑country clinical data and no current commercial approvals.
The company highlights more than $100 million of historical funding, including about $30 million from DARPA and NIH and over $50 million from Asian investors, a patent estate of 25 issued U.S. patents and 32 international patents, and reports no serious device‑related adverse events to date for Lumee Oxygen or Lumee Glucose.